ENVB (Enveric Biosciences) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 05, 2025)

View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Enveric Biosciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Enveric Biosciences's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Enveric Biosciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Enveric Biosciences Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Enveric Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Executives

Frank Pasqualone	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney	officer: Chief Financial Officer	10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey	officer: Chief Financial Officer	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil	director	C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson	director	1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel	officer: Chief Technical Officer	3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker	director, officer: Chief Executive Officer	3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini	officer: Chief Scientific Officer	155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward	officer: Chief Financial Officer	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind	director
Marcus Schabacker	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer	director	150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson	director, officer: CEO and Chairman	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins	officer: Chief Medical Officer	C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103